Adjudin is primarily investigated for its potential as a male contraceptive. It works by disrupting the connection between sperm cells and the supporting cells in the testes, leading to the release of immature sperm that are unable to fertilize an egg. This effect is reversible, making it a promising candidate for non-hormonal birth control in men. Beyond contraception, Adjudin has shown anti-inflammatory and immunomodulatory properties, which are being explored in the context of autoimmune diseases and organ transplantation. Research is also underway to evaluate its role in cancer therapy, particularly in targeting testicular and prostate cancers due to its ability to induce cell death in certain tumor lines. Most applications remain in preclinical or experimental stages.